ONO PHARMACEUTICAL CO., LTD.

Notes to Consolidated Financial Statements (Income taxes)

Fiscal year ended March 31, 2022

16. Income Taxes

(1) Deferred Income Taxes

Amounts of deferred tax assets and deferred tax liabilities at each consolidated fiscal year end are as follows:

	Millions o	Millions of Yen			
	March 31, 2021	March 31, 2022			
Deferred tax assets	¥ 34,242	¥ 25,074			
Deferred tax liabilities	1,052	1,009			
Net	¥ 33,190	¥ 24,064			

Details and movements of deferred tax assets and deferred tax liabilities by major sources are as follows:

For the year ended March 31, 2021

,	Millions of Yen											
		ance at 131, 2020	Chang Accou Poli	inting	balance	stated e at April 2020	Recogn profit		Recognin ot comprehincome	her nensive	Mar	ance at rch 31, 021
Deferred tax assets												
Accrued bonuses	¥	1,730	¥	_	¥	1,730	¥	37	¥	_	¥	1,768
Accrued enterprise tax		1,087		_		1,087		250		_		1,337
Expenses for research and												
development commissions		41.105				41 107		2.061				45.060
and others		41,107		_		41,107		3,961		_		45,068
Investment securities		33		_		33		(10)		_		23
Property, plant, and		2 206				2 206		(00)				2.226
equipment		2,306		420		2,306		(80)		_		2,226
Intangible assets		61		438		500		6		_		506
Retirement benefit		2.006				2 006		100	/1	1.045)		2 004
liabilities		3,806		_		3,806		123	(1	1,045)		2,884
Other accounts payable Provision for		1,817		_		1,817		502		_		2,319
		(241				(241						(241
patent royalties		6,341		_		6,341		950		_		6,341
Others		5,664		-		5,664		859		-		6,523
Total	¥	63,953	¥	438	¥	64,391	¥	5,650	¥ ()	1,045)	¥	68,996
Deferred tax liabilities												
Property, plant, and												
equipment	¥	(4,138)	¥	_	¥	(4,138)	¥	(234)	¥	-	¥	(4,372)
Intangible assets		(2,755)		185		(2,570)		(10)		-		(2,580)
Investment securities		(23,302)		_	((23,302)		(35)	(5	5,516)		(28,854)
Others		(0)				(0)		0		_		_
Total	¥	(30,195)	¥	185	¥	(30,010)	¥	(279)	¥ (5	5,516)	¥	(35,806)
Net	¥	33,758	¥	623	¥	34,381	¥	5,371	¥ (6	5,561)	¥	33,190

•	Millions of Yen				
	Recognized in other				
	Balance at	Recognized in	comprehensive	Balance at	
_	April 1, 2021	profit or loss	income (loss)	March 31, 2022	
Deferred tax assets					
Accrued bonuses	¥ 1,768	¥ 18	¥ –	¥ 1,785	
Accrued enterprise tax	1,337	(1,081)	=	256	
Expenses for research and development					
commissions and others	45,068	(10,348)	=	34,720	
Investment securities	23	(23)	=	=	
Property, plant, and equipment	2,226	32	=	2,258	
Intangible assets	506	(182)	=	324	
Retirement benefit liabilities	2,884	75	(88)	2,871	
Other accounts payable	2,319	1,152	=	3,471	
Provision for patent royalties	6,341	(6,341)	=	=	
Others	6,523	1,017	_	7,540	
Total	¥ 68,996	¥ (15,682)	¥ (88)	¥ 53,226	
Deferred tax liabilities					
Property, plant, and equipment	¥ (4,372)	¥ 124	¥ –	¥ (4,248)	
Intangible assets	(2,580)	1,228	_	(1,352)	
Investment securities	(28,854)	30	5,262	(23,561)	
Others					
Total	¥ (35,806)	¥ 1,382	¥ 5,262	¥ (29,161)	
Net	¥ 33,190	¥ (14,300)	¥ 5,174	¥ 24,064	

Notes: 1. The differences between deferred tax expense and the amount recognized in profit or loss are exchange differences on translation of foreign operations and others.

- 2. The effective statutory tax rate used to calculate deferred tax assets and deferred tax liabilities as of March 31, 2021 and 2022 in Japan is 30.6%.
- 3. Taxable temporary differences associated with investments in subsidiaries, for which deferred tax liabilities were not recognized, amounted to \(\frac{\frac{1}}{4}\),098 million and \(\frac{1}{2}\),436 million as of March 31, 2021 and 2022, respectively. This is because the Group is able to control the timing of the reversal of the temporary differences, and it is certain that the temporary differences will not reverse in the foreseeable future.
- 4. The Group has changed the accounting policy for configuration or customization costs in cloud computing agreements. This change in accounting policy has been applied retrospectively to related accounts for the previous fiscal year.

(2) Income Tax Expense

Details of income tax expense are as follows:

	Millions of Yen		
	For the year ended	For the year ended	
	March 31, 2021	March 31, 2022	
Current tax expense	¥ 30,736	¥ 10,018	
Deferred tax expense	(5,344)	14,323	
Total	¥ 25,392	¥ 24,340	

Note: The Group is subject to corporate tax, inhabitant tax, and enterprise tax in Japan, which in the aggregate resulted in an applicable tax rate for current tax expense of 30.6% for the years ended March 31, 2021 and 2022. Overseas subsidiaries use the income tax rates of the countries in which they are located.

(3) Reconciliation of Applicable Tax Rates and Average Actual Tax Rates Details of the differences between the applicable tax rates and average actual tax rates are as follows:

	For the year ended March 31, 2021	For the year ended March 31, 2022
Applicable tax rates	30.6 %	30.6 %
Permanent non-deductible items	0.2	0.2
Non-taxable dividends	(0.1)	(0.1)
Tax credit for research and development, etc.	(6.2)	(7.7)
Others	0.7	0.2
Average actual tax rates	25.2 %	23.2 %

Note: The applicable tax rates used to reconcile the applicable tax rates and average actual tax rates are the Company's effective statutory tax rates.